Somewhat Favorable Press Coverage Somewhat Unlikely to Impact MEI Pharma (NASDAQ:MEIP) Stock Price
Headlines about MEI Pharma (NASDAQ:MEIP) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MEI Pharma earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.1306499716909 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
MEI Pharma (NASDAQ MEIP) traded up 0.74% during midday trading on Monday, reaching $2.74. The company’s stock had a trading volume of 33,154 shares. The firm has a 50-day moving average price of $2.78 and a 200 day moving average price of $1.97. The stock has a market capitalization of $100.76 million, a price-to-earnings ratio of 80.59 and a beta of 1.56. MEI Pharma has a 52-week low of $1.34 and a 52-week high of $3.26.
A number of equities research analysts have weighed in on MEIP shares. Zacks Investment Research upgraded MEI Pharma from a “hold” rating to a “strong-buy” rating and set a $1.75 target price for the company in a research report on Tuesday, May 9th. Cann restated an “outperform” rating on shares of MEI Pharma in a research report on Wednesday, May 24th. Finally, Oppenheimer Holdings, Inc. set a $7.00 target price on MEI Pharma and gave the stock a “buy” rating in a research report on Wednesday, June 14th.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-mei-pharma-nasdaqmeip-stock-price/1487244.html.
MEI Pharma Company Profile
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Receive News & Ratings for MEI Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.